Literature DB >> 21240258

Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor.

Anna M Dahlin1, Maria L Henriksson, Bethany Van Guelpen, Roger Stenling, Ake Oberg, Jörgen Rutegård, Richard Palmqvist.   

Abstract

The aim of this study was to relate the density of tumor infiltrating T cells to cancer-specific survival in colorectal cancer, taking into consideration the CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) screening status. The T-cell marker CD3 was stained by immunohistochemistry in 484 archival tumor tissue samples. T-cell density was semiquantitatively estimated and scored 1-4 in the tumor front and center (T cells in stroma), and intraepithelially (T cells infiltrating tumor cell nests). Total CD3 score was calculated as the sum of the three CD3 scores (range 3-12). MSI screening status was assessed by immunohistochemistry. CIMP status was determined by quantitative real-time PCR (MethyLight) using an eight-gene panel. We found that patients whose tumors were highly infiltrated by T cells (total CD3 score ≥7) had longer survival compared with patients with poorly infiltrated tumors (total CD3 score ≤4). This finding was statistically significant in multivariate analyses (multivariate hazard ratio, 0.57; 95% confidence interval, 0.31-1.00). Importantly, the finding was consistent in rectal cancer patients treated with preoperative radiotherapy. Although microsatellite unstable tumor patients are generally considered to have better prognosis, we found no difference in survival between microsatellite unstable and microsatellite stable (MSS) colorectal cancer patients with similar total CD3 scores. Patients with MSS tumors highly infiltrated by T cells had better prognosis compared with intermediately or poorly infiltrated microsatellite unstable tumors (log rank P=0.013). Regarding CIMP status, CIMP-low was associated with particularly poor prognosis in patients with poorly infiltrated tumors (multivariate hazard ratio for CIMP-low versus CIMP-negative, 3.07; 95% confidence interval, 1.53-6.15). However, some subset analyses suffered from low power and are in need of confirmation by independent studies. In conclusion, patients whose tumors are highly infiltrated by T cells have a beneficial prognosis, regardless of MSI, whereas the role of CIMP status in this context is less clear.

Entities:  

Mesh:

Year:  2011        PMID: 21240258     DOI: 10.1038/modpathol.2010.234

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  97 in total

1.  Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Authors:  Anna Sophie Berghoff; Gerda Ricken; Dorothee Wilhelm; Orsolya Rajky; Georg Widhalm; Karin Dieckmann; Peter Birner; Rupert Bartsch; Matthias Preusser
Journal:  J Neurooncol       Date:  2016-07-19       Impact factor: 4.130

2.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.

Authors:  Panagiotis Balermpas; Daniel Martin; Ulrike Wieland; Margret Rave-Fränk; Klaus Strebhardt; Claus Rödel; Emmanouil Fokas; Franz Rödel
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer.

Authors:  Jian L Campian; Guneet Sarai; Xiaobu Ye; Shanthi Marur; Stuart A Grossman
Journal:  Head Neck       Date:  2014-04-15       Impact factor: 3.147

Review 4.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

5.  Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery.

Authors:  Koichiro Mori; Yuji Toiyama; Susumu Saigusa; Hiroyuki Fujikawa; Junichiro Hiro; Minako Kobayashi; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

6.  Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer.

Authors:  Louise J Jones; Claude Chelala; Emanuela Gadaleta; Pauline Fourgoux; Stefano Pirró; Graeme J Thorn; Rachel Nelan; Alastair Ironside; Vinothini Rajeeve; Pedro R Cutillas; Anna E Lobley; Jun Wang; Esteban Gea; Helen Ross-Adams; Conrad Bessant; Nicholas R Lemoine
Journal:  NPJ Breast Cancer       Date:  2020-08-21

7.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

8.  Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer.

Authors:  Jian L Campian; Xiaobu Ye; Malcolm Brock; Stuart A Grossman
Journal:  Cancer Invest       Date:  2013-02-22       Impact factor: 2.176

Review 9.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

10.  Lymphopenia and its association with survival in patients with locally advanced cervical cancer.

Authors:  Emily S Wu; Titilope Oduyebo; Lauren P Cobb; Diana Cholakian; Xiangrong Kong; Amanda N Fader; Kimberly L Levinson; Edward J Tanner; Rebecca L Stone; Anna Piotrowski; Stuart Grossman; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2015-11-11       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.